Table 2 Association of clinicopathologic variables with low-molecular weight (LMW) cfDNA concentration after bead purification and size-selection
LMW cfDNA (ng/mL) | p-value | |
|---|---|---|
Full cohort (N = 113) | 23.8 (14.9, 44.4) | |
Benign (N = 22) | 15.5 (9.3, 25.8) | 0.006 |
Cancer (N = 91) | 25.8 (16.0, 49.6) | |
Histologic subtype | 0.006 | |
G1 EAC (N = 16) | 35.3 (14.1, 83.5) | |
G2 EAC (N = 15) | 23.4 (17.6, 28.0) | |
G3 EAC (N = 16) | 23.9 (17.8, 41.9) | |
UPSC (N = 15) | 21.3 (14.3, 32.9) | |
CS (N = 15) | 32.2 (17.9, 79.0) | |
LMS (N = 8) | 65.4 (45.7, 164.3) | |
CCC (N = 6) | 13.8 (8.0, 26.0) | |
Grade | 0.04 | |
Grade 1 (N = 16) | 35.3 (14.1, 83.5) | |
Grade 2 (N = 15) | 23.4 (17.6, 28.0) | |
Grade 3 (N = 60) | 24.9 (16.1, 51.3) | |
Stage of cancer | 0.03 | |
Stage I (N = 42) | 24.0 (14.7, 47.1) | |
Stage II (N = 16) | 24.3 (16.8, 37.8) | |
Stage III (N = 22) | 26.6 (18.8, 36.6) | |
Stage IV (N = 11) | 57.2 (16.4, 246.1) | |
Lymphovascular space invasion | 0.04 | |
Absent | 21.6 (12.8, 39.3) | |
Present | 30.4 (17.8, 54.6) | |
% Myometrial invasion | 0.32 | |
Tumor size | 0.006 | |
Lymph node status | ||
Negative | 23.4 (14.4, 44.5) | 0.39 |
Positive | 30.4 (17.0, 44.4) | |
Age | 0.38 | |
Body mass index | 0.53 | |
Race | ||
White | 23.8 (14.9, 36.2) | 0.66 |
Non-White | 24.3 (14.8, 46.6) | |